Surrozen(SRZNW)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: Surrozen is a public biotech focused on Wnt signaling antibodies for neurological indications, operating as a micro-cap with 59 employees. The company is pre-revenue or early-revenue stage with $11M in FY 2025 revenue against $21M R&D spend.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
59
Open Jobs
0
About Surrozen
AI assessmentNot HiringNo open roles listed right now. Follow Surrozen to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Surrozen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$11M
Pipeline & Clinical Trials
SZN-8141 for Injection
Diabetic Macular Edema (DME)Clinical Trials (1)
NCT07817121A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
Phase 1Help build intelligence for Surrozen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.